X4 Pharmaceuticals Inc (XFOR)

$3.50 +0.10 (2.94%)
Market Cap 347.02M
Revenue (ttm) 35.11M
Net Income (ttm) -79.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -225.58%
Debt to Equity Ratio 0.49
Volume 1,252,900
Avg Vol 718,864
Day's Range N/A - N/A
Shares Out 99.15M
Stochastic %K 32%
Beta 0.39
Analysts Strong Sell
Price Target $11.60

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 529 8300
Address:
61 North Beacon Street, 4th Floor, Boston, United States
TwongStocks
TwongStocks Sep. 10 at 6:22 PM
$XFOR Some interesting comments from Adam Craig today. https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/avk4X4LRbKukjcipVLXZ5g 1) He said when they first came onboard that they thought the 4WARD trial was overpowered. After having their statisticians review the trial, they concluded that they could run an adequately powered trial with only 126 patients. FDA agreed. 2) He also disclosed that they had issues with the previous CRO (Contract Research Organization) that was running the trial. They switched to Parexel. When he joined the company last year, the 4WARD trial did not have any US patients in the trial. With Parexel in place, they are seeing increased screenings and more US patients, which gives them confidence that they'll be able to complete enrollment later this year. 3) Once they finish enrollment later this year, they expect the last patient to reach 52 week follow up by end of next year. With topline data 8-12 weeks after that.
0 · Reply
TwongStocks
TwongStocks Sep. 9 at 11:06 AM
$XFOR Updated Investor Presentation. I assume they will use this slide deck at the Wells Fargo Conference on Sept 10. https://investors.x4pharma.com/static-files/7f60a057-e0b6-45a9-ac0d-551568d6bad1 Slide 3: 4WARD Trial full enrollment expected in Q4 2026, topline expected in 1H 2028, potential approval in late 2028/early 2029. Slide 17: $208M as of June 30. 145.6m shares fully diluted. Cash runway into 2029.
1 · Reply
Joe_BLow_88
Joe_BLow_88 Sep. 8 at 11:58 PM
$XFOR In view of today's update, they'll need to raise about an additional $170M to get through 1H 2029 to reach commericalization phase for CN, if FDA approved. Note holder Hercules has no reason to be forgiving. Shareholders will take the hit on the imminent dilution. This one has made an early entry into the valley of death. It looks like a promising drug. Too bad it's unlikely to make a lot of money for shareholders.
0 · Reply
LF5
LF5 Sep. 8 at 6:29 PM
$XFOR I’m in at 3.25 and will hold for a swing trade if necessary. Looks like it has good upside potential.
0 · Reply
h8ster
h8ster Sep. 8 at 5:34 PM
$XFOR Delayed enrollment completion and extending the topline data to 2028 killed anything positive from that PR. That much of an extension creates a near term dilutive story. Even thought hey have cash through 2028, its irrelevant. The market will see the Hercules debt being due July 1, 2027 as a risk. And for unprofitable, speculative bio, extending targets/goals is a massive rug pull top the pps. Being that they have no near term catalysts remaining for 2026, there's no reason to play this in the near term. This play is done.
4 · Reply
CargoShorts4Life
CargoShorts4Life Sep. 8 at 3:29 PM
$XFOR great news tanks. Awesome.
0 · Reply
St0ckt0k101
St0ckt0k101 Sep. 8 at 3:07 PM
$XFOR 👀📉
0 · Reply
focafoca99
focafoca99 Sep. 8 at 11:38 AM
$XFOR noted a positive FDA Type C meeting outcome for its 4WARD Phase 3 trial.
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 11:03 AM
$XFOR Announces Positive Outcome from FDA Type C Meeting https://www.globenewswire.com/news-release/2026/09/08/3357473/0/en/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-meeting.html • FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial. • Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028.
0 · Reply
Pope25
Pope25 Sep. 2 at 3:03 PM
$XFOR anyone feeling ballsy enough to buy calls on this?
1 · Reply
Latest News on XFOR
X4 Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 10, 2026, 9:30 AM EDT - 3 days ago

X4 Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

Sep 9, 2026, 7:00 AM EDT - 4 days ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals announces results from Type C Meeting with FDA

2026-09-08T11:25:46.000Z - 5 days ago

X4 Pharmaceuticals announces results from Type C Meeting with FDA

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

Sep 8, 2026, 7:00 AM EDT - 5 days ago

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 1, 2026, 4:30 PM EDT - 11 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation

2026-08-26T13:00:11.000Z - 18 days ago

X4 Pharmaceuticals treatment of congenital neutropenia gets orphan designation

X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)

2026-08-06T21:40:20.000Z - 5 weeks ago

X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 6, 2026, 4:15 PM EDT - 5 weeks ago

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

X4 Pharmaceuticals Quarterly report: Q2 2026

X4 Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

X4 Pharmaceuticals Earnings release: Q2 2026

X4 Pharmaceuticals initiated with an Overweight at Wells Fargo

2026-07-10T10:25:42.000Z - 2 months ago

X4 Pharmaceuticals initiated with an Overweight at Wells Fargo

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 7, 2026, 4:30 PM EDT - 2 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

2026-07-01T11:20:53.000Z - 2 months ago

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

CAMP

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

Jul 1, 2026, 7:00 AM EDT - 2 months ago

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 3 months ago

X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

X4 Pharmaceuticals initiated with an Outperform at Leerink

2026-06-02T10:35:48.000Z - 3 months ago

X4 Pharmaceuticals initiated with an Outperform at Leerink

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 7:00 AM EDT - 3 months ago

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)

2026-05-07T06:33:22.000Z - 4 months ago

X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)

X4 Pharmaceuticals files $300M mixed securities shelf

2026-05-07T01:47:41.000Z - 4 months ago

X4 Pharmaceuticals files $300M mixed securities shelf

X4 Pharmaceuticals Registration statement: Registration filing

May 6, 2026, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals Registration statement: Registration filing

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 7:15 AM EDT - 4 months ago

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Quarterly report: Q1 2026

X4 Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Earnings release: Q1 2026

X4 Pharmaceuticals announces EC approval of Xolremdi

2026-04-29T16:37:43.000Z - 4 months ago

X4 Pharmaceuticals announces EC approval of Xolremdi

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

Apr 29, 2026, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

X4 Pharmaceuticals Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Proxy statement: Proxy filing

X4 Pharmaceuticals Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Proxy statement: Proxy filing

X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)

2026-03-17T11:20:56.000Z - 6 months ago

X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)

X4 Pharmaceuticals sees cash runway through 2028

2026-03-17T11:20:44.000Z - 6 months ago

X4 Pharmaceuticals sees cash runway through 2028

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 7:15 AM EDT - 6 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 6 months ago

X4 Pharmaceuticals Earnings release: Q4 2025

X4 Pharmaceuticals Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 6 months ago

X4 Pharmaceuticals Annual report: Q4 2025

X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 6 months ago

X4 Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

X4 Pharmaceuticals initiated with a Buy at Guggenheim

2026-03-09T10:51:50.000Z - 6 months ago

X4 Pharmaceuticals initiated with a Buy at Guggenheim

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 6 months ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor

2026-02-27T12:07:32.000Z - 6 months ago

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Feb 27, 2026, 7:00 AM EST - 6 months ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 12:30 PM EST - 7 months ago

X4 Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals Slides: Corporate presentation

Feb 10, 2026, 6:00 AM EST - 7 months ago

X4 Pharmaceuticals Slides: Corporate presentation

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 7 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel

2025-12-05T11:40:18.000Z - 9 months ago

X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel

X4 Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

X4 Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

2025-11-10T11:25:30.000Z - 10 months ago

X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 10 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

2025-11-05T17:20:16.000Z - 10 months ago

X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

X4 Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

X4 Pharmaceuticals Quarterly report: Q3 2025

X4 Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

X4 Pharmaceuticals Earnings release: Q3 2025

X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

2025-11-05T12:05:28.000Z - 10 months ago

X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 10 months ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 27, 2025, 7:05 PM EDT - 10 months ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85

2025-10-24T10:41:05.000Z - 10 months ago

X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 24, 2025, 12:37 AM EDT - 10 months ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 10 months ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Sep 17, 2025, 7:00 AM EDT - 12 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Registration statement: Registration Filing

Sep 10, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Registration statement: Registration Filing

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 13, 2025, 7:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Aug 12, 2025, 7:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

X4 Pharmaceuticals Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

X4 Pharmaceuticals Quarterly report: Q2 2025

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 16, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 10, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025, 4:12 PM EDT - 1 year ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q1 2025

X4 Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Quarterly report: Q1 2025

X4 Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings release: Q1 2025

X4 Pharmaceuticals Slides: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Slides: Q1 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:03 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 24, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q4 2024

X4 Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Annual report: Q4 2024

X4 Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Earnings release: Q4 2024

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Proxy statement: Proxy Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 19, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 6, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 24, 2025, 7:36 AM EST - 1 year ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Jan 13, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 11:00 AM EST - 1 year ago

X4 Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

X4 Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

X4 Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Earnings Call Transcript: Q3 2024

X4 Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Quarterly report: Q3 2024

X4 Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Earnings release: Q3 2024

X4 Pharmaceuticals Slides: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals Slides: Q3 2024

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:40 PM EDT - 1 year ago

X4 Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

X4 Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 2:35 PM EDT - 2 years ago

X4 Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q2 2024

X4 Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Quarterly report: Q2 2024

X4 Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q2 2024

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 8, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Transcript: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: Study Update

X4 Pharmaceuticals Press release: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Press release: Study Update

X4 Pharmaceuticals Slides: Study Update

Jun 27, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: Study Update

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 27, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 29, 2024, 4:30 PM EDT - 2 years ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 2:00 PM EDT - 2 years ago

X4 Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 9, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q1 2024

X4 Pharmaceuticals Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Quarterly report: Q1 2024

X4 Pharmaceuticals Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q1 2024

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

X4 Pharmaceuticals Transcript: FDA Announcement

Apr 29, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: FDA Announcement

X4 Pharmaceuticals Press release: FDA Announcement

Apr 29, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Press release: FDA Announcement

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

X4 Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Proxy statement: Proxy Filing

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:37 AM EDT - 2 years ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 29, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

X4 Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 9:30 AM EDT - 2 years ago

X4 Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

X4 Pharmaceuticals Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 9:30 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: 23rd Annual Needham Virtual Healthcare Conference

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Apr 1, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals Slides: Investor Presentation

Mar 28, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Slides: Investor Presentation

X4 Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings Call Transcript: Q4 2023

X4 Pharmaceuticals Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Annual report: Q4 2023

X4 Pharmaceuticals Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

X4 Pharmaceuticals Earnings release: Q4 2023

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

TwongStocks
TwongStocks Sep. 10 at 6:22 PM
$XFOR Some interesting comments from Adam Craig today. https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/avk4X4LRbKukjcipVLXZ5g 1) He said when they first came onboard that they thought the 4WARD trial was overpowered. After having their statisticians review the trial, they concluded that they could run an adequately powered trial with only 126 patients. FDA agreed. 2) He also disclosed that they had issues with the previous CRO (Contract Research Organization) that was running the trial. They switched to Parexel. When he joined the company last year, the 4WARD trial did not have any US patients in the trial. With Parexel in place, they are seeing increased screenings and more US patients, which gives them confidence that they'll be able to complete enrollment later this year. 3) Once they finish enrollment later this year, they expect the last patient to reach 52 week follow up by end of next year. With topline data 8-12 weeks after that.
0 · Reply
TwongStocks
TwongStocks Sep. 9 at 11:06 AM
$XFOR Updated Investor Presentation. I assume they will use this slide deck at the Wells Fargo Conference on Sept 10. https://investors.x4pharma.com/static-files/7f60a057-e0b6-45a9-ac0d-551568d6bad1 Slide 3: 4WARD Trial full enrollment expected in Q4 2026, topline expected in 1H 2028, potential approval in late 2028/early 2029. Slide 17: $208M as of June 30. 145.6m shares fully diluted. Cash runway into 2029.
1 · Reply
Joe_BLow_88
Joe_BLow_88 Sep. 8 at 11:58 PM
$XFOR In view of today's update, they'll need to raise about an additional $170M to get through 1H 2029 to reach commericalization phase for CN, if FDA approved. Note holder Hercules has no reason to be forgiving. Shareholders will take the hit on the imminent dilution. This one has made an early entry into the valley of death. It looks like a promising drug. Too bad it's unlikely to make a lot of money for shareholders.
0 · Reply
LF5
LF5 Sep. 8 at 6:29 PM
$XFOR I’m in at 3.25 and will hold for a swing trade if necessary. Looks like it has good upside potential.
0 · Reply
h8ster
h8ster Sep. 8 at 5:34 PM
$XFOR Delayed enrollment completion and extending the topline data to 2028 killed anything positive from that PR. That much of an extension creates a near term dilutive story. Even thought hey have cash through 2028, its irrelevant. The market will see the Hercules debt being due July 1, 2027 as a risk. And for unprofitable, speculative bio, extending targets/goals is a massive rug pull top the pps. Being that they have no near term catalysts remaining for 2026, there's no reason to play this in the near term. This play is done.
4 · Reply
CargoShorts4Life
CargoShorts4Life Sep. 8 at 3:29 PM
$XFOR great news tanks. Awesome.
0 · Reply
St0ckt0k101
St0ckt0k101 Sep. 8 at 3:07 PM
$XFOR 👀📉
0 · Reply
focafoca99
focafoca99 Sep. 8 at 11:38 AM
$XFOR noted a positive FDA Type C meeting outcome for its 4WARD Phase 3 trial.
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 11:03 AM
$XFOR Announces Positive Outcome from FDA Type C Meeting https://www.globenewswire.com/news-release/2026/09/08/3357473/0/en/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-meeting.html • FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial. • Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028.
0 · Reply
Pope25
Pope25 Sep. 2 at 3:03 PM
$XFOR anyone feeling ballsy enough to buy calls on this?
1 · Reply
TwongStocks
TwongStocks Aug. 26 at 6:26 PM
$XFOR Mavorixafor received orphan drug designation for the treatment of congenital neutropenia. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722
0 · Reply
TwongStocks
TwongStocks Aug. 26 at 11:16 AM
$XFOR Adam Craig, Executive Chairman, will present at the Wells Fargo 21st Annual Healthcare Conference. Sept 10 at 9:30am ET. Registration link for the webcast https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/avk4X4LRbKukjcipVLXZ5g
0 · Reply
starkist
starkist Aug. 14 at 11:44 AM
$XFOR something is going on here ...whatever it is ...i haven't a clue.. been sitting on this for too many years.. and only once in very blue moon do i come here and take a peak.. but i like this hint of northern movement.
1 · Reply
Pope25
Pope25 Aug. 10 at 8:05 PM
$XFOR ok boys, time to load up
0 · Reply
TwongStocks
TwongStocks Aug. 6 at 8:33 PM
$XFOR 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000150169726000068/xfor-20260630.htm • 99,146,743 shares outstanding as of July 31 • $2.4M in product revenue. $6.4M in license revenue from Norgine, which included $5.5M in milestone payments. Total revenue $8.8M. • Net loss per share ($0.13)
2 · Reply
Jeff226
Jeff226 Aug. 5 at 2:56 PM
$XFOR
0 · Reply
StockScanners
StockScanners Jul. 11 at 10:37 PM
$XFOR keep watch if this holds above 4.24
0 · Reply
IN0V8
IN0V8 Jul. 10 at 3:24 PM
$XFOR Buy Wells Fargo initiates coverage with overweight rating Wells Fargo initiates target price $11
0 · Reply
dl42
dl42 Jul. 10 at 11:55 AM
$XFOR here some positive news
0 · Reply
Jeff226
Jeff226 Jun. 30 at 6:17 PM
$XFOR
0 · Reply
Pope25
Pope25 Jun. 26 at 2:49 AM
$XFOR might go visit the low 3’s again
0 · Reply
Skusek
Skusek May. 31 at 11:29 PM
$XFOR Still heavily unprofitable: X4 reported a 2025 net loss of about $79 million and continues to post significant quarterly losses despite restructuring efforts.•.
1 · Reply